Business
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today announced a collaboration with Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, supported by funding from Google Cloud, to build a Google Cloud-native peptide design platform intended to dramatically inc
About this update from Decoy Therapeutics Inc.
[{"type":"text","content":"Partnership supported by funding from Google Cloud will increase Decoy's computational peptide design bandwidth by 25-100x","length":126,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass. and HOUSTON, March 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across multiple viruses, today announced a collaboration with Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, supported by funding from Google Cloud, to build a Google Cloud-native peptide design platform intended to dramatically increase the speed and scale of antiviral peptide discovery.","length":623,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Decoy Therapeutics, Inc)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Decoy Therapeutics, Inc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":104,"url":"https://media.zenfs.com/en/prnewswire.com/f3867f8a7694a91d3360742d3fdb246a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9Rx5QeyO4QyCQkFqooOe9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f3867f8a7694a91d3360742d3fdb246a","width":400,"height":104}},"href":"https://mma.prnewswire.com/media/2859955/Decoy_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""At its core, this collaboration is about speed," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. "By working with Quantori and leveraging Google Cloud's scalable infrastructure, we are building a foundation that will allow Decoy to fundamentally accelerate the pace at which we can design new peptides. This will result in a dramatic improvement in our ability to explore chemical space, iterate on designs and translate computational insights into real therapeutic candidates. This will be foundational to realizing the intent of D-MAVs – single antiviral drugs that are effective against multiple viruses for both prevention and treatment, thus addressing multiple valuable commercial opportunities and important public health use cases in one drug program."","length":802,"tagName...